ABCELLERA BIOLOGICS INC

AbCellera Biologics is a biotechnology company whose core business model relies on the commercial exploitation of animals. The company's primary revenue is derived from discovering and developing therapeutic antibodies, a process that inherently requires animal testing. AbCellera's proprietary platform, which screens millions of antibody candidates, utilizes animal-derived components and in vivo models as a standard part of its drug discovery and development workflow for partners in the pharmaceutical industry. This places the company's central commercial activity within the scope of animal exploitation, as defined by the exclusion policy.

While the company's Code of Business Conduct and Ethics references a commitment to high standards, it does not provide a policy prohibiting or limiting animal testing. The code focuses on legal compliance and ethical decision-making frameworks but offers no specific guidance or restrictions on the use of animals in research. The absence of a public animal welfare policy or commitment to alternative methods indicates that animal use is an accepted and integral component of AbCellera's business operations.